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Background: The causes of chronic fatigue syndrome (CFS) and idiopathic chronic fatigue (ICF) are not clearly
known, and there are no definitive treatments for them. Therefore, patients with CFS and ICF are interested in
Oriental medicine or complementary and alternative medicine. For this reason, the effectiveness of complementary
and alternative treatments should be verified. We investigated the effectiveness of two forms of acupuncture added
to usual care for CFS and ICF compared to usual care alone.
Methods: A three-arm parallel, non-blinded, randomized controlled trial was performed in four hospitals. We
divided 150 participants into treatment and control groups at the same ratio. The treatment groups (Group A,
body acupuncture; Group B, Sa-am acupuncture) received 10 sessions for 4 weeks. The control group (Group
C) continued usual care alone. The primary outcome was the Fatigue Severity Scale (FSS) at 5 weeks after
randomization. Secondary outcomes were the FSS at 13 weeks and a short form of the Stress Response
Inventory (SRI), the Beck Depression Inventory (BDI), the Numeric Rating Scale (NRS), and the EuroQol-5
Dimension (EQ-5D) at 5 and 13 weeks.
Results: Group A showed significantly lower FSS scores than Group C at 5 weeks (P = 0.023). SRI scores were
significantly lower in the treatment groups than in the control group at 5 (Group A, P = 0.032; B, P <0.001)
and 13 weeks (Group A, P = 0.037; B, P <0.001). Group B showed significantly lower BDI scores than Group C
at 13 weeks (P = 0.007). NRS scores from the treatment groups were significantly reduced compared to
control at 5 (Group A and B, P <0.001) and 13 weeks (Group A, P = 0.011; B, P = 0.002).
Conclusions: Body acupuncture for 4 weeks in addition to usual care may help improve fatigue in CFS and
ICF patients.
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Fatigue generally refers to severe exhaustion during and
after daily activities or to a lack of energy. Prolonged
and repetitive fatigue seriously influences the quality of
life [1]. Fatigue that continues for more than 6 months is
defined as chronic fatigue, and chronic fatigue for which
no medical explanation exists is classified as chronic fa-
tigue syndrome (CFS) or idiopathic chronic fatigue (ICF).
The diagnostic criteria for CFS are as follows: (1) the indi-
vidual has severe chronic fatigue for 6 or more consecutive
months that is not due to ongoing exertion or other med-
ical conditions associated with fatigue; (2) the fatigue sig-
nificantly interferes with daily activities and work; and (3)
the individual concurrently has four or more of eight
specific symptoms. These symptoms include the following:
(i) postexertional malaise lasting for more than 24 h; (ii)
unrefreshing sleep; (iii) significant impairment of short-
term memory or concentration; (iv) muscle pain; (v) multi-
joint pain without swelling or redness; (vi) headaches of a
new type, pattern, or severity; (vii) tender cervical or axil-
lary lymph nodes; and (viii) a sore throat that is frequent
or recurring. Information about CFS can be found at
http://www.cdc.gov/cfs/case-definition/index.html. Cases
that cannot be categorized according to the above diagnos-
tic criteria are included under ICF [2, 3]. The worldwide
prevalence of ICF and CFS is approximately 10 % and
1 %, respectively [4]. The causes of CFS and ICF are
not clearly known. Immune regulatory dysfunction, vari-
ous inflammatory conditions, neuroendocrine dysfunction,
central nervous system impairments, and stress are the
hypothesized causes of them. There is no definitive cure
for CFS and ICF. Therefore, patients with CFS and ICF
are interested in Oriental medicine or complementary and
alternative medicine, and various alternative approaches
have been used to treat these patients [3, 5, 6]. For this
reason, the effectiveness of complementary and alternative
treatments should be verified.
Acupuncture and moxibustion are among the most
widely used treatments in Oriental medicine. Thus far,
some systematic reviews have reported favorable outcomes
regarding the effects of acupuncture and moxibustion on
CFS. However, the overall finding of these reviews is that
firm evidence for the effects of acupuncture and moxibus-
tion is lacking because of the poor methodological quality
of the studies included [7–11]. In this trial, we evaluated
the effectiveness of two acupuncture methods: (1) body
acupuncture, a traditional acupuncture method widely
used for many years in China, Korea, and Japan, in which
treatment is applied to the whole body, and (2) Sa-am
acupuncture, a Korean traditional acupuncture method
developed by Sa-am in the Chosun Dynasty, in which
the five-phase theory and mother-child reinforcement-
reduction principle are applied to the selection of points
and needling manipulation [12–14]. This study aimed toevaluate the overall effects of acupuncture treatment by
comparing outcomes in a treatment group receiving body
acupuncture or Sa-am acupuncture with outcomes in a
control group receiving usual care.
Methods
This was a three-arm, randomized, nonblinded, con-
trolled, and parallel-designed trial. This trial was con-
ducted in four clinical research centers of South Korea
from August 2012 to May 2013. The participants were
recruited by each center (Gwangju, Seoul, Jecheon, and
Daejeon) through advertisements in local newspapers, the
websites of local universities, and posters displayed in hos-
pitals. Details of the study design are available in a previ-
ous publication [15]. The flow diagram and CONSORT
(Consolidated Standards of Reporting Trials) checklist are
provided in Additional files 1 and 2.
Ethical considerations
This study was approved by the institutional review
boards of the Gwangju Oriental Hospital of Dongshin
University, Kyung Hee University Hospital at Gangdong,
Jecheon Oriental Hospital of Semyung University, and
Daejeon Oriental Hospital of Daejeon University. All par-
ticipants provided written informed consent. The study
was conducted according to the principles of the Declar-
ation of Helsinki [16].
Inclusion criteria
The inclusion criteria for the study were as follows [2, 17]:
1. Adult men and women aged 19 to 65 years.
2. Presenting major symptoms of continuous or
recurrent fatigue due to unknown causes of at least
6 months’ duration.
3. Absence of abnormal findings in the following:
blood pressure (BP) test, blood tests (hemoglobin
(Hb), hematocrit (Hct), white blood cells (WBC),
and glucose), biochemical marker tests (aspartate
aminotransferase (AST), alanine aminotransferase
(ALT), and creatinine), serum electrolyte tests
(sodium (Na), potassium (K), and chloride (Cl)),
thyroid function tests (TFTs) (thyroid stimulating
hormone (TSH) and free thyroxine (FT4)),
pregnancy test for women of child-bearing age, chest
radiography (CXR), and electrocardiography (ECG).
Test findings were considered “abnormal” with refer-
ence to the following values:
a. BP: Diastolic BP ≥90 mmHg (average of 2
measurements, each taken at an interval of at least 2
min after a rest period of at least 5 min in a sitting
position).
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or <36 %, for males and non-pregnant females,
respectively; WBC ≥11,000/mm3 and random
plasma glucose ≥200 mg/dL for all participants.
c. Biochemical marker tests: AST or ALT ≥50 IU/L;
creatinine ≥1.5 mg/dL.
d. Electrolyte tests: Na <135 or ≥145 mmol/L; K <3.5
or ≥5.5 mmol/L; Cl <97 or ≥110 mmol/L.
e. TFTs: TSH <0.35 or ≥5.50 mIU/mL; FT4 <0.89
or ≥1.76 ng/dL.
f. Pregnancy test: Urine sample positive for human
chorionic gonadotropin (hCG).
g. CXR: Active pulmonary tuberculous lesions.
h. ECG: Indications of heart disease requiring
treatment, such as arrhythmia, ischemic heart
disease, or cardiomegaly.4. Numeric Rating Scale (NRS) [18] score ≥4 during
the 7 days preceding the screening tests.
5. Providing written informed consent after being
informed of the objectives and particularities of
the clinical trial, and agreeing to participate in the
trial.
Exclusion criteria
The exclusion criteria for the study were as follows [2, 17]:
1. History of chronic fatigue or a present illness that
might trigger chronic fatigue, including (but not
limited to) the following disorders:a. Organic causes: Acute or chronic liver diseases
(hepatitis, liver cirrhosis), anemia, tuberculosis,
chronic lung diseases, cardiovascular diseases (heart
failure, hypertension), endocrine/metabolic diseases
(diabetes, hyperthyroidism, hypothyroidism, severe
obesity with a body mass index (BMI) of ≥35 kg/
m2), autoimmune diseases (rheumatoid arthritis,
systemic lupus erythematosus, multiple sclerosis),
malignant tumors, or infectious diseases.
b. Psychosocial causes: Major depression, anxiety
neurosis, a recent severe stress, schizophrenia,
alcoholism, or an eating disorder (anorexia nervosa,
bulimia nervosa).2. Medication with the following drugs during the
preceding 2 weeks: Antihypertensive drugs,
antidepressants, antianxiety agents, sleeping pills, or
antihistamines.
3. Female participants who were pregnant, breast-
feeding, or planning for pregnancy.
4. Participating in other clinical trials.
5. Undertaking excessive workloads (for example,
undertaking multiple jobs).6. History of hypersensitivity reaction to acupuncture
treatment.
7. Residents of collective dwelling facilities, such as
social welfare institutions.
8. Failure to provide written informed consent.
9. Considered unfit for the trial by the principal
investigator because of other reasons.
Randomization
A statistician used a computer program (Strategic
Applications Software (SAS), version 9.1.3 (SAS Institute
Inc., Cary, NC, USA) to generate the random allocation
sequence. We used a stratified block randomization
scheme with four institutions chosen as strata. The
generated sequences were sealed in opaque envelopes
and delivered to each center, where they were stored
in double-locked cabinets. Randomization was conducted
for participants who satisfied all selection criteria. The re-
searcher opened the random allocation envelopes in order
in front of the participants and assigned them to 1 of 3
groups. The clinical research coordinator allotted partici-
pant identification codes and recorded them in the case
report forms. The opened envelopes were stored separ-
ately in double-locked cabinets.
Blinding
This was a nonblinded study.
Interventions
The eligible participants were allocated randomly into
three groups, including Group A, Group B, or Group C.
In each group, participants received their allocated treat-
ment. Participants in treatment group received 10 ses-
sions of acupuncture treatment for 4 weeks, 2 to 3 times
a week, using stainless steel disposable needles (0.25-
mm diameter, 30-mm length; Dongbang Acupuncture
Inc., South Korea). Participants were informed about the
body acupuncture and Sa-am acupuncture used in this
study as follows: “In this study, two types of acupuncture
will be used. One type will be body acupuncture, which
is based on traditional Chinese medicine (TCM). The
other type will be Sa-am acupuncture, a traditional
Korean acupuncture method.” The practitioners, doctors
of Korean medicine having more than 3 years of prac-
tical experience, participated in a training session to en-
sure that treatments were administered consistently. The
practitioners were allowed to communicate with the par-
ticipants about treatment, lifestyle, etc.
Group A (body acupuncture plus usual care group)
The participants in Group A were treated in the supine
position at the acupoints described below. The acupoints
were selected based on published literature and text-
books [12, 19]:
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0.5 to 1.5 cun).
2. Bilateral GB20 (perpendicular needling toward the
opposite-side eye up to a depth of 0.3 to 1.0 cun).
3. Bilateral BL11, BL13, BL15, BL18, BL20, and BL23
(downward oblique or horizontal needling up to a
depth of 0.5 to 1.0 cun).
All needles were retained for 15 min without twirling.
In TCM, the qi moves through the meridians at a rate of
6 cun per respiratory cycle. The length of the meridians
and collaterals equals 1620 cun. Thus, 270 (1620/6) re-
spiratory cycles are required for qi to make one cycle
through the body. If an adult breathes 18 times per min,
15 min (270/18) are needed for qi to make one cycle
[20]. Therefore, the needle retaining time was 15 min.Group B (Sa-am acupuncture plus usual care group)
The participants assigned to Group B received treat-
ment at the following acupoints while sitting on a chair.
The acupoints were selected based on a published lit-
erature [13]:
1. LU8 (downward oblique needling up to a depth of
0.5 to 0.7 cun)
2. SP3 (upward oblique needling up to a depth of 0.3
to 0.5 cun)
3. HT8 (downward oblique needling up to a depth of
0.3 to 0.5 cun)
4. BL15 (upward oblique or horizontal needling up to a
depth of 0.5 to 1.0 cun)
5. CV6 (downward oblique needling up to a depth of
0.5 to 1.0 cun).
All needles were retained for 15 min after being
twirled nine times (at LU8, SP3, and HT8) or six times
(at BL15 and CV6).Group C (usual care alone group)
The participants randomized to Group C did not receive
acupuncture treatment; however, they did receive the ne-
cessary usual care [21, 22].Concomitant treatments
In all groups, usual care consisted of the use of any form
of concomitant treatment, including Oriental medicine
treatments (for example, acupuncture for conditions other
than chronic fatigue, moxibustion, herbal medicine),
Western medicine (for example, conventional medication,
injections), or self-care (for example, dietary supplements,
exercise). All groups were provided with educational ma-
terials about chronic fatigue.Primary outcome
The Fatigue Severity Scale (FSS) score at 5 weeks after
randomization was used as the primary endpoint. The
FSS included nine questions, scored on a scale of 1 to 7,
which were used to evaluate the participant’s fatigue
level during the previous week [23, 24].
Secondary outcomes
A short form of the Stress Response Inventory (SRI),
consisting of 22 questions covering the following three
categories, was used to evaluate stress: somatization
(nine items), depression (eight items), and anger (five
items) [25]. The Beck Depression Inventory (BDI) con-
sisted of 21 questions assessing the cognitive, emotional,
motivational, and somatic symptoms of depression. Each
item was scored on a 4-point scale from 0 to 3 [26]. The
NRS used a horizontal straight line with numbers from
0 to 10 and indications of “no fatigue” on the far left and
“most severe fatigue experienced” on the far right end.
The participants were asked to select the number that
represented the level of their own fatigue [18]. The
EuroQol-5 Dimension (EQ-5D) tool assessed health-
related quality of life. It consisted of the EQ-Visual
Analogue Scale (VAS), which scored the participant’s
health condition on a straight line marked from 0 to
100, and the EQ-5D descriptive system, which inquired
about five dimensions of the participant’s current health
status. Information about the EQ-5D can be found at
http://www.euroqol.org/.
Other assessments
We assessed the treatment expectancy survey [27] com-
pleted by each participant, and confirmed that the Centers
for Disease Control and Prevention (CDC)’s diagnostic
criteria for CFS [2] was fulfilled.
Adverse events
Practitioners recorded all unexpected and unintended
responses as reported by each participant on an adverse
event report form. The relationship between acupunc-
ture treatment and adverse events was graded from 1 to
6 (1 = definitely related, 2 = probably related, 3 = pos-
sibly related, 4 = probably not related, 5 = definitely not
related, and 6 = unknown).
Statistical analysis
In order to have a 90 % chance of detecting a mean dif-
ference of 0.915 in the primary outcome at a significance
level of 5 %, 40 patients were required per group. Based
on the effect size described in a previous pilot study
[12], we assumed a mean change of 0.9632 in the treat-
ment group and 0.0482 in the control group, with a
common standard deviation of 1.1479. Allowing for a 20
% dropout rate, 50 patients were required per group
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available in a previous publication [15]. A computer pro-
gram (SAS, version 9.1.3) was used to perform the
analysis. The hypothesis of this study was as follows: H0 :
μ1 = μ3, μ2 = μ3, H1 : not H0 (μ1, FSS mean score for
Group A at 5 weeks after randomization; μ2, FSS mean
score for Group B at 5 weeks after randomization;
and μ3, FSS mean score for Group C at 5 weeks after
randomization). The analysis set consisted of a full ana-
lysis set (FAS; that is, the set of participants who were as
close as possible to the intention-to-treat (ITT) principle)
and a per-protocol set (PPS; that is, the set of participants
who were more compliant with the protocol) [28]. The
FAS was used for the main analysis.
A mixed model for repeated measures (MMRM)
method was used to determine the differences between
the experimental groups and the control group; the
treatment, visit time, and institution were the fixed fac-
tors, and the participant was the random factor [29].
Additionally, an analysis of covariance (ANCOVA) was
performed by replacing the missing data using the last
observation carried forward (LOCF) method, and the re-
sults were compared with the results of the MMRM
method. In ANCOVA, the primary and secondary out-
comes at 5 and 13 weeks after randomization were the
dependent variables, the baseline value was the covariate,
and the group and the institution were the fixed factors.
The analyses were performed at the 5 % significance level.
When the ANCOVA produced significant results, a post-
hoc analysis was conducted to determine which groups
showed differences. For the socio-demographic character-
istics and treatment expectancy, the mean and standard
deviation were determined from the continuous data, and
the frequency and percentage were determined from the
categorical data. The subgroup analysis of FSS was per-
formed in CFS and ICF groups.
Results
Flow of participants
We selected 150 participants from 195 screened individ-
uals. Gwangju, Kyung Hee, and Jecheon hospitals re-
cruited 45 participants each, and Daejeon center
recruited 15 participants. The selected participants were
randomly allocated to a treatment group (Group A or B)
or the control group (Group C). Among the participants,
three from Group A, two from Group B, and two from
Group C dropped out of the study (see Additional file
1). The reasons the participants dropped out of the
study are presented in Additional file 1.
Baseline characteristics
The sociodemographic characteristics of the participants
are shown in Table 1. No significant differences were ob-
served between the groups regarding age, sex, height,weight, education level, occupation, marital status, meal
regularity, exercise, smoking, and use of alcohol. Accord-
ing to the CFS questionnaire, 63 participants (42 %)
could be classified as having CFS. The frequency of par-
ticipants with CFS was similar within the different
groups. The treatment expectancy was significantly dif-
ferent between the treatment groups and the control
group (Table 1).
Findings for the primary outcome
The FSS score from Group A at 5 weeks after
randomization was significantly lower than that of
Group C (Table 2).
Findings for the secondary outcomes
The FSS scores at 13 weeks after randomization were not
different between the groups. The SRI-short form scores
were significantly lower in the treatment groups than in
the control group at both 5 and 13 weeks after
randomization. Although no difference was observed in
the BDI score among the groups at 5 weeks after
randomization, the score from Group B was significantly
reduced in comparison to Group C at 13 weeks after
randomization. The NRS scores from the treatment
groups were significantly reduced compared to those
from the control group at both 5 and 13 weeks after
randomization. The EQ-5D did not show any differ-
ences among the groups at 5 and 13 weeks after
randomization (Table 2).
Sensitivity analysis
After processing the missing values with the LOCF
method, the results of the ANCOVA indicated that the
scores from the FSS, SRI-short form, BDI, and NRS were
significantly reduced in the treatment groups compared
to the control group at both 5 and 13 weeks after
randomization. The EQ-5D was significantly different
between Group A and C at 5 weeks after randomization
and between both treatment groups and the control
group at 13 weeks after randomization (Table 3).
The results of the PPS analysis were similar to those of
the FAS. However, the SRI-short form score at 13 weeks
after randomization was not significantly different be-
tween Group A and C (Table 4).
The FSS score at 5 weeks after randomization, per-
formed on the FAS after correcting for the treatment
expectancy in each group, showed a significant differ-
ence between Group A and C (P = 0.028). A signifi-
cant difference was not observed between Group B
and C (P = 0.129).
Subgroup analysis
The CFS group comprised 21 patients in Group A, 23 in
Group B, and 19 in Group C. Furthermore, the ICF
Table 1 Baseline characteristics of study participants
Variable Group A (n = 49) Group B (n = 51) Group C (n = 50)
Age, years 44.9 ± 11.4 39.6 ± 11.5 41.1 ± 11.9
Sex, M/F 15 (30.6)/34 (69.4) 18 (35.3)/33 (64.7) 19 (38.0)/31 (62.0)
Height, cm 162.2 ± 6.8 165.3 ± 8.9 164.4 ± 8.8
Weight, kg 59.8 ± 10.8 63.0 ± 12.5 62.8 ± 12.4
Duration of chronic fatigue
6 months to 1 year 17 (34.7) 13 (25.5) 18 (36.0)
1 year to 5 years 17 (34.7) 23 (45.1) 24 (48.0)
>5 years 15 (30.6) 15 (29.4) 8 (16.0)
Previous treatment
Medication 0 (0.0) 2 (3.9) 0 (0.0)
Oriental medicine treatment 2 (4.1) 4 (7.8) 1 (2.0)
Therapeutic exercise 1 (2.0) 3 (5.9) 0 (0.0)
Psychotherapy 0 (0.0) 0 (0.0) 0 (0.0)
Other treatment 6 (12.2) 4 (7.8) 5 (10.0)
Chronic fatigue syndrome, M/F 3 (6.1)/18 (36.7) 6 (11.8)/17 (33.3) 6 (12.0)/13 (26.0)
Education >12 years 28 (57.1) 39 (76.5) 35 (70.0)
Job 36 (73.5) 39 (76.5) 40 (80.0)
Marriage 38 (77.6) 32 (62.7) 37 (74.0)
Irregular meals 18 (36.7) 18 (35.3) 19 (38.0)
Exercise
Yes 29 (59.2) 24 (47.1) 23 (46.0)
Weekly average frequency 3.4 ± 2.0 2.8 ± 1.5 3.4 ± 1.6
Average time per session, h 1.2 ± 0.9 1.4 ± 0.6 1.1 ± 0.5
Tobacco use 8 (16.3) 10 (19.6) 8 (16.0)
Alcohol use 23 (46.9) 21 (41.2) 21 (42.0)
Treatment expectancy 6.9 ± 1.5 6.1 ± 1.4 4.5 ± 2.4
Yes (6 to 9) 40 (81.6) 37 (72.5) 18 (36.0)
No (1 to 5) 9 (18.4) 14 (27.5) 32 (64.0)
Data are presented as either mean ± SD or number (%), where appropriate
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B, and 31 in Group C. Results of MMRM analysis of FSS
score in each group and results of the subgroup-
treatment effect interaction test are presented in Table 5.
Concomitant treatments
Usual care methods for fatigue reported during the
trial period were nutritional supplements and exercise
(working out, walking, riding a stationary bicycle,
swimming, and hiking). In terms of individual groups,
Group A had two patients who took nutritional sup-
plements, three patients who performed exercise, and
one patient who combined nutritional supplements
with exercise; whereas Group B had two patients who
took nutritional supplements, one patient who re-
ceived a nutritional supplement injection, and three
patients who performed exercise. In Group C, twopatients took nutritional supplements and three pa-
tients performed exercise. None of the participants in
Group A or C received any additional acupuncture
during the study period, other than the therapy pro-
vided as part of the study. One participant in Group
B had received acupuncture for lower back pain,
which was unrelated to fatigue.
Adverse events
A total of 10 adverse events were reported by 10 partici-
pants. Of these events, two were determined to be linked
either to acupuncture or possibly associated with acupunc-
ture, and the symptom severity was mild in both cases. All
participants who experienced adverse events improved
during the research period and continued to partici-
pate in the experiment. Although two serious adverse
events were reported, they were not related to the
Table 2 Results of mixed model for repeated measures (MMRM) analysis of full analysis set (FAS)
Outcome Group Baseline 5 weeks 13 weeks
Mean (SD) Mean (SD) Pa LSMD (95 % CI)a Mean (SD) Pa LSMD (95 % CI)a
FSS A 4.67 (1.27) 3.38 (1.01) 0.023 −0.43 (−0.81, −0.05) 3.34 (1.17) 0.075 −0.36 (−0.74, 0.03)
B 4.75 (1.07) 3.58 (1.12) 0.151 −0.29 (−0.66, 0.08) 3.51 (1.19) 0.290 −0.23 (−0.62, 0.15)
C 4.48 (1.27) 4.47 (1.18) - - 4.28 (1.24) - -
SRI-short form A 62.56 (17.95) 42.21 (14.18) 0.032 −6.01 (−11.58, −0.44) 42.28 (14.33) 0.037 −6.19 (−12.06, −0.31)
B 55.67 (14.40) 42.10 (13.66) <0.001 −9.33 (−14.72, −3.95) 39.81 (13.55) <0.001 −10.80 (−16.49, −5.12)
C 60.04 (18.16) 56.47 (18.03) - - 57.41 (20.46) - -
BDI A 16.41 (8.36) 9.02 (6.92) 0.252 −1.56 (−3.94, 0.83) 9.63 (6.39) 0.231 −1.68 (−4.16, 0.81)
B 15.00 (7.67) 8.88 (7.66) 0.052 −2.34 (−4.70, 0.02) 7.89 (7.15) 0.007 −3.25 (−5.71, −0.80)
C 15.30 (7.05) 13.36 (6.39) - - 14.28 (8.54) - -
NRS A 6.59 (1.44) 4.42 (1.98) <0.001 −0.92 (−1.45, −0.40) 4.77 (2.22) 0.011 −0.70 (−1.26, −0.14)
B 6.55 (1.27) 4.52 (1.70) <0.001 −0.90 (−1.42, −0.39) 4.51 (1.95) 0.002 −0.85 (−1.40, −0.29)
C 6.40 (1.40) 6.53 (1.36) - - 6.42 (1.69) - -
EQ-5D A 0.84 (0.10) 0.91 (0.11) 0.909 −0.01 (−0.04, 0.03) 0.92 (0.11) 0.844 0.01 (−0.03, 0.04)
B 0.87 (0.09) 0.91 (0.09) 0.522 0.01 (−0.02, 0.05) 0.94 (0.08) 0.074 0.03 (0.00, 0.07)
C 0.88 (0.11) 0.88 (0.10) - - 0.87 (0.15) - -
LSMD, least squares mean difference; CI, confidence interval; FSS, fatigue severity scale; SRI-short form, short form of the stress response inventory;
BDI, Beck depression inventory; NRS, numeric rating scale; EQ-5D, EuroQol-5 dimension.
aP value with 95 % CI, Dunnett’s adjustment
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hospitalization because of a traffic accident) (Table 6).
Discussion
After 10 treatment sessions in 4 weeks, the mean FSS
score in Group A improved significantly compared toTable 3 Results of analysis of covariance (ANCOVA) of full analysis s
Outcome Group Baseline 5 weeks
Mean (SD) Mean (SD) Pa LSM
FSS A 4.67 (1.27) 3.39 (1.12) <0.001 −1
B 4.75 (1.07) 3.62 (1.13) <0.001 −0
C 4.48 (1.27) 4.43 (1.19) - -
SRI-short form A 62.56 (17.95) 43.07 (15.49) <0.001 −1
B 55.67 (14.40) 42.65 (14.24) <0.001 −1
C 60.04 (18.16) 56.82 (18.10) - -
BDI A 16.41 (8.36) 9.43 (6.98) <0.001 −5
B 15.00 (7.67) 9.04 (7.61) <0.001 −4
C 15.30 (7.05) 13.84 (6.80) - -
NRS A 6.59 (1.44) 4.56 (2.09) <0.001 −1
B 6.55 (1.27) 4.58 (1.70) <0.001 −1
C 6.40 (1.40) 6.46 (1.39) - -
EQ-5D A 0.84 (0.10) 0.96 (0.11) 0.025 0.0
B 0.87 (0.09) 0.91 (0.09) 0.107 0.0
C 0.88 (0.11) 0.88 (0.09) - -
LSMD, least squares mean difference; CI, confidence interval; FSS, fatigue sever
BDI, Beck depression inventory; NRS, numeric rating scale; EQ-5D, EuroQol-5 di
aP value with 95 % CI, Dunnett’s adjustmentGroup C. This result is consistent with findings in a pre-
liminary study on body acupuncture [12]. A previous
study reported that the optimal FSS cut-off point to de-
marcate between fatigue and normal groups was 3.22
(sensitivity 84.1 %, specificity 85.7 %) [24]. Using this
cut-off point as the reference standard, the mean post-et (FAS)
13 weeks
D (95 % CI)a Mean (SD) Pa LSMD (95 % CI)a
.14 (−1.57, −0.71) 3.32 (1.17) <0.001 −1.01 (−1.48, −0.55)
.95 (−1.38, −0.52) 3.58 (1.20) <0.001 −0.80 (−1.26, −0.34)
4.24 (1.25) - -
5.24 (−21.32, −9.16) 43.61 (15.31) <0.001 −15.01 (−21.96, −8.06)
1.58 (−17.45, −5.72) 40.19 (13.57) <0.001 −14.97 (−21.67, −8.26)
57.36 (20.30) - -
.03 (−7.60, −2.47) 10.02 (6.40) <0.001 −4.74 (−7.56, −1.91)
.63 (−7.17, −2.10) 8.20 (7.01) <0.001 −5.88 (−8.67, −3.09)
14.22 (8.32) - -
.96 (−2.72, −1.20) 4.78 (2.32) <0.001 −1.64 (−2.51, −0.78)
.93 (−2.68, −1.18) 4.59 (1.92) <0.001 −1.81 (−2.67, −0.96)
6.34 (1.70) - -
4 (0.00, 0.08) 0.91 (0.11) 0.008 0.06 (0.01, 0.11)
3 (−0.01, 0.07) 0.93 (0.09) 0.005 0.06 (0.02, 0.11)
0.87 (0.15) - -
ity scale; SRI-short form, short form of the stress response inventory;
mension
Table 4 Results of mixed model for repeated measures (MMRM) analysis of per-protocol set (PPS)
Outcome Group Baseline 5 weeks 13 weeks
Mean (SD) Mean (SD) Pa LSMD (95 % CI)a Mean (SD) Pa LSMD (95 % CI)a
FSS A 4.70 (1.22) 3.38 (1.10) 0.017 −0.45 (−0.84, −0.07) 3.34 (1.17) 0.074 −0.36 (−0.75, 0.03)
B 4.74 (1.09) 3.58 (1.12) 0.090 −0.33 (−0.71, 0.04) 3.51 (1.19) 0.230 −0.26 (−0.64, 0.12)
C 4.52 (1.26) 4.47 (1.18) - - 4.24 (1.22) - -
SRI-short form A 62.59 (17.77) 42.21 (14.18) 0.039 −5.92 (−11.58, −0.27) 42.28 (14.33) 0.063 −5.69 (−11.64, 0.26)
B 55.50 (14.23) 42.10 (13.66) <0.001 −9.22 (−14.69, −3.76) 39.81 (13.55) <0.001 −10.34 (−16.10, −4.58)
C 59.26 (18.34) 56.47 (18.03) - - 56.67 (20.11) - -
BDI A 16.59 (8.60) 9.02 (6.92) 0.338 −1.39 (−3.82, 1.04) 9.64 (6.39) 0.386 −1.35 (−3.88, 1.18)
B 15.12 (7.67) 8.88 (7.66) 0.086 −2.14 (−4.54, 0.25) 7.89 (7.15) 0.018 −2.92 (−5.41, −0.43)
C 14.91 (6.78) 13.36 (6.39) - - 14.00 (8.42) - -
NRS A 6.57 (1.42) 4.42 (1.98) <0.001 −1.01 (−1.54, −0.48) 4.77 (2.22) 0.006 −0.76 (−1.33, −0.20)
B 6.53 (1.28) 4.52 (1.70) <0.001 −0.98 (−1.50, −0.46) 4.51 (1.95) <0.001 −0.90 (−1.46, −0.34)
C 6.47 (1.38) 6.53 (1.36) - - 6.38 (1.69) - -
EQ-5D A 0.84 (0.10) 0.91 (0.11) 0.948 0.00 (−0.04, 0.03) 0.92 (0.11) 0.785 0.01 (−0.03, 0.05)
B 0.87 (0.10) 0.91 (0.09) 0.494 0.01 (−0.02, 0.05) 0.94 (0.08) 0.067 0.03 (0.00, 0.07)
C 0.88 (0.11) 0.88 (0.10) - - 0.87 (0.15) - -
LSMD, least squares mean difference; CI, confidence interval; FSS, fatigue severity scale; SRI-short form, short form of the stress response inventory;
BDI, Beck depression inventory; NRS, numeric rating scale; EQ-5D, EuroQol-5 dimension
aP value with 95 % CI, Dunnett’s adjustment
Kim et al. Trials  (2015) 16:314 Page 8 of 13treatment FSS score for Group A (3.38) can be considered
a near-normal value. Group B demonstrated improvement
after 10 treatment sessions in 4 weeks, with an FSS score
of 3.58. However, the change was not statistically signifi-
cant and contradicted findings in a preliminary study of
Sa-am acupuncture [13]. The discrepancy between the re-
sults of the present and preliminary study may be due to
the higher proportion of participants (approximately 28
%) with fatigue morbidity lasting less than 6 months in the
preliminary study. The shorter duration of morbidity in
the preliminary study likely eased the task of alleviating
symptoms compared to the longer duration in the present
study. Additionally, in the preliminary study, a sham acu-
puncture group was used as a control, and the Multiple
Fatigue Scale (MFS) was used for assessment, neither of
which was employed in this study. The MFS is a recon-
stituted fatigue assessment tool developed in 2000 andTable 5 Results of the mixed model for repeated measures (MMRM
Subgroup Baseline 5 weeks
Mean (SD) Mean (SD) Pa LSMD (95 % CI)a
CFS (n = 63) A 5.50 (0.94) 3.62 (1.22) 0.993 0.02 (−0.51, 0.56)
B 5.06 (0.87) 3.75 (1.00) 0.768 −0.14 (−0.66, 0.38)
C 4.74 (0.81) 4.39 (0.97) - -
ICF (n = 87) A 4.06 (1.14) 3.21 (0.99) 0.008 −0.68 (−1.20, −0.16)
B 4.50 (1.16) 3.44 (1.21) 0.188 −0.37 (−0.89, 0.14)
C 4.32 (1.47) 4.51 (1.29) - -
LSMD, least squares mean difference; CI, confidence interval; CFS, chronic fatigue sy
aP value with 95 % CI, Dunnett’s adjustment. bSubgroup treatment effect interactionbased on the Fatigue Assessment Inventory [30], and its
correlation with the FSS has not yet been determined.
These differences in the duration of symptoms, control
groups, and assessment tools likely contributed to dif-
ferent results between this study and the preliminary
study. When a significant result is required for only
one of multiple primary endpoints in order to consider
a trial positive, each endpoint must be tested with a sig-
nificance level that has been corrected for multiplicity
[31]. For the two primary endpoint tests in this study,
we corrected type I errors using Dunnett’s method [32],
and based on the results of the hypothesis tests, one of
two null hypotheses was rejected. Therefore, the results
of our trial can be considered positive.
In the auxiliary parameters, the FSS score in Group A
decreased to 3.34 at 13 weeks after randomization; how-
ever, this trend was not significantly different from results) analysis of fatigue severity scale (FSS) score in the subgroups
13 weeks
Interactionb Mean (SD) Pa LSMD (95 % CI)a Interactionb
0.585c 3.43 (1.21) 0.924 −0.08 (−0.64, 0.48) 0.854c
3.95 (1.05) 0.901 −0.09 (−0.64, 0.46)
4.44 (1.23) - -
3.27 (1.15) 0.078 −0.48 (−1.01, 0.04)
3.16 (1.20) 0.235 −0.35 (−0.87, 0.17)
4.19 (1.25) - -
ndrome; ICF, idiopathic chronic fatigue
. cP value





End date Intensity Causal
relationship





1 20120918 20120920 Mild Probably No change None Cured
Right thumb
numbness, pain
1 20120913 20121120 Mild Possibly No change None Improved













No change Medication Improved
Coccyx fracture 1 20121213 Unknown Moderate Definitely
not
No change Medication Improved
Right shoulder pain 1 20121105 20121130 Mild Definitely
not
No change Medication Improved
Left second finger
pain
1 20121101 20121203 Mild Definitely
not
No change Medication Improved
Upper respiratory
infection
3 20121123 20121201 Mild Probably
not
No change None Improved
20121127 20121203 Mild Definitely
not
No change None Improved
20121021 20121027 Moderate Definitely
not
No change None Improved
Kim et al. Trials  (2015) 16:314 Page 9 of 13in the control group. Therefore, the effects of body
acupuncture therapy appears to have been short-term.
Group A showed significant improvements in both the
SRI-short form and NRS scores at 5 and 13 weeks after
randomization. Group B showed significant improvements
in the SRI-short form and NRS scores at 5 and 13 weeks
after randomization, and in the BDI score at 13 weeks
after randomization. Both treatment groups showed im-
provements in stress or depression, symptoms that are
closely associated with fatigue, suggesting that body acu-
puncture and Sa-am acupuncture may positively influence
fatigue in multidimensional or comprehensive aspects.
Both Groups A and B showed a significantly lower NRS
score, suggesting that body acupuncture and Sa-am acu-
puncture may positively influence the intensity of fatigue.
Reportedly, the FSS assesses the impact rather than the in-
tensity of fatigue [33, 34]. Thus, the NRS may measure the
intensity of fatigue more efficiently than the FSS. Based on
the analysis of the SRI-short form, NRS, and BDI results,
it was difficult to conclude that Sa-am acupuncture had
no effect to improve fatigue. Though it was beyond the
scope of this study, the EQ-5D-assisted measurements of
the health-related quality of life were performed as a cost-
utility analysis of an economic evaluation. The results
showed that neither treatment group exhibited significant
improvements at 5 and 13 weeks after randomization.
This might be because the treated participants did not ex-
perience any changes in their quality of life or because the
EQ-5D was a generic instrument that was not disease-
specific and, thus, was not sensitive enough to respond to
changes in fatigue severity [35]. Similar to the primaryevaluation variable analysis, the results obtained using
Dunnett’s test were presented for the secondary evaluation
variables. However, type I errors were not corrected for all
the comparisons in this trial. All comparisons, except for
the primary analysis designated before beginning the
study, pose a risk of increased type I errors due to multiple
tests. The results of secondary analyses do not provide an-
swers to the research question; they should be used for
obtaining useful information from the trial [31].
The natural history of chronic fatigue/CFS is still of
concern: many patients reported either residual symp-
toms or disability at follow-up and a progression or
worsening of symptoms was seen in some. [36]. There-
fore, it was difficult to specify a standard for recurrent
fatigue in the inclusion criteria. To date, no specific
diagnostic test has been established for CFS [37]; as a re-
sult, CFS is diagnosed on the basis of exclusion, subject-
ive clinical interpretation, and patient self-report [38]. In
this trial, we included participants by relying on exclu-
sion based on laboratory tests and case definitions. In
addition, we used subjective questionnaires when evalu-
ating the outcomes.
At the beginning of this study, we had planned to
process the missing data by the LOCF method. However,
since the LOCF method can present problems, such as
introducing a bias from incorrect estimation of the vari-
ance in effect estimates, the main analysis method was
changed to the MMRM approach, and the LOCF
ANCOVA method was added as a secondary analysis. The
results from the two methods were then compared,
and we found that the LOCF ANCOVA underestimated
Kim et al. Trials  (2015) 16:314 Page 10 of 13the P value. This is consistent with the results of previous
studies noting that conservative behavior of LOCF is not
guaranteed. Therefore, care should be taken when using
the LOCF method for analysis of clinical trial data [39,
40]. Because disease severity is different for CFS and ICF,
post-hoc subgroup analysis was performed to investigate
differences in the therapeutic effects in each group (CFS
or ICF). The interpretation of subgroup analysis does not
ascertain whether the therapeutic effects exist in each sub-
group, but tries to ascertain whether the interaction
between the subgroups and the therapeutic effects is sig-
nificant. Since there was no interaction between the sub-
groups and therapeutic effects in the present study,
acupuncture appears to have been equally effective in all
the subgroups. However, because this was an exploratory
subgroup analysis, the reproducibility needs to be con-
firmed in other trials [41].
Although there are no traditional Chinese medical terms
that describe CFS and ICF, the concepts may be similar to
consumptive disease (a general term for chronic deficiency
diseases due to consumption of yin, yang, qi, and blood)
or fatigue due to overexertion (a diseased state caused by
overexertion, manifested as fatigue, lassitude, shortness of
breath upon exertion, and spontaneous sweating) [14, 42].
It was reported that the visceral pattern identification of
CFS/ICF can be classified into spleen-lung qi deficiency,
spleen-kidney yang deficiency, heart-spleen blood defi-
ciency, and liver-kidney yin deficiency [42, 43]. However,
we did not apply pattern identification because we could
not find a tool that was sufficiently validated.
In this trial, the acupoints used in Group A were se-
lected to relieve the mind, clear the spirit, tranquilize the
body to free it from tension, and regulate the functions of
the internal organs [12]. Sa-am acupuncture is largely di-
vided into fixed pattern, transformed pattern, and experi-
enced prescription. Transformed pattern (LU8, SP3, HT8)
and experienced prescription (BL15, CV6) were applied to
the participants in Group B [44, 45]. In TCM, needle ther-
apy harmonizes the qi that flows through the meridians of
the body. Harmonizing the qi is effective when the qi is
obtained in response to acupuncture needling (de qi,
needling sensation). Among the methods for harmonizing
the qi, cui qi or hastening the qi, is a way of facilitating de
qi if qi does not come when it should, whereas xing qi or
moving the qi, can aid in transferring the needling re-
sponse to the disease location. Bu xie, or supplementation
and draining, is a method of reinforcing what is lacking
and reducing what is excessive. Manual acupuncture can
be categorized as basic, assistant, bu xie, as well as com-
prehensive bu xie manual. The basic manual method is a
simple technique that involves induction of cui qi and xing
qi, as well as bu xie. This technique includes twirling and
needle retention. Twirling involves turning the needle to
the left and to the right, whereas needle retention isdesigned to maintain the needle at a specific point for a
period of time. These basic manual methods can be ap-
plied as basic bu xie manual acupuncture techniques.
Among the basic bu xie manual methods, the directional
method includes ‘bu’, which is supplementation via inser-
tion of the needle in the direction of the needled channel
flow and ‘xie’, which is draining via insertion of the needle
in the direction opposite to the channel flow. The nine-six
method, which is another basic bu xie manual method,
distinguishes the number of movements involved in twir-
ling or needle retention, where the number 9 represents
‘bu’ and 6 represents ‘xie’ [14, 46, 47]. If one locates the
point accurately, qi may be obtained immediately after
one inserts the needle to the right depth in the right direc-
tion [47]. In the present study, needling was performed in
Group A by obtaining accurate acupoints and a suitable
depth of needling, along with proper perception by the
acupuncturist. Therefore, although twirling and bu xie
were not performed in Group A, it is believed that the qi
was correctly obtained. In the original literature on Sa-am
acupuncture, detailed descriptions of bu xie were not pro-
vided, presumably because it was a general contemporary
bu xie method or because it was a method based on the
traditional bu xie method from Neijing [48]. In Group B,
needling was performed by the manual methods (twirling,
needle retention, and directional methods) used in the
preliminary study [13], as well as the nine-six method
added in this trial.
This study has three primary strengths. First, the exter-
nal validity of the study was improved by performing a
pragmatic clinical trial (PCT). Clinical trials can have ei-
ther an explanatory or a pragmatic design. An explanatory
clinical trial (ECT) evaluates what interventions work in
ideal (controlled) situations, whereas a PCT evaluates
whether interventions work in everyday clinical practice
settings. Since PCTs reflect clinical practice, the patient
population range is broader than in ECTs, and PCTs often
allow for individualized treatments for patients [21, 22]. In
previous studies, acupuncture therapy for chronic fatigue
has often been limited to CFS [7–11]. In this study, we
used usual care as the control and we included ICF pa-
tients, as well as CFS patients, in the subject population.
Moreover, the study was intended to better reflect real
clinical situations through its multi-institutional clinical
trial design. However, we did not evaluate the long-term
effects of the treatment investigated, unlike general PCTs.
In addition, we used a standardized treatment and have
therefore studied the effectiveness of the selected points.
Second, the results from the FAS and PPS were presented
together. A FAS is the collection of participants who most
closely fit the ITT principle of the clinical trial, and which
minimizes the number of participants excluded from ana-
lysis. A PPS is a subset of the FAS and consists of fully
compliant participants. In this study, since the results for
Kim et al. Trials  (2015) 16:314 Page 11 of 13the two sets were similar, confidence in the trial outcomes
was increased [28]. Third, adverse events were reported in
detail. We described the symptoms and signs, dates of
presentation and disappearance, causal relationships with
test interventions, acupuncture-related actions, treat-
ments, and results. During the clinical trial period, 2 of
the 150 participants (1.3 %) showed acupuncture-related
adverse events. The safety of acupuncture therapy has
been reported previously [49–51] and is confirmed herein.
This study has some weaknesses. First, the effectiveness
of acupuncture in this study included both specific effects
and context effects (expectation, patient-practitioner rela-
tionship, etc.) [52]. Although the results compensated for
treatment expectations, which are presented in the results
section as a reference, the specific effects of acupuncture
could not be isolated owing to the study design. It was re-
ported that the identities of CFS patients are challenged
when the legitimacy of their illness is questioned, and doc-
tors can support patients in coping with their disease by
encouraging them instead of casting suspicion upon them
[53]. In the present study, free communication between
the patients and the acupuncturist was allowed. However,
acupuncturists did not actively provide attention, advice,
or empathy. Therefore, it is thought that the patient-
practitioner relationship did not significantly impact the
treatment effects. Second, there is lower internal validity
owing to the allowance of individualized usual care (ex-
cept acupuncture therapy for chronic fatigue). Although
the percentage of participants who reported using usual
care during the trial period was not high (Group A: 12 %;
B: 12 %; and C: 10 %), its effect on the study’s outcomes
could not be evaluated. Third, fatigue could not be evalu-
ated from multidimensional aspects. The FSS is one of the
best known and most used fatigue scales [33, 54]. Since
the reliability and validity of the Korean-language version
of the FSS has been proven [24], it was used as the pri-
mary evaluation instrument for this study. Although the
FSS consists of multiple items, it is still a one-dimensional
scale and, therefore, is not sufficient for the evaluation of
complex aspects of fatigue such as its physical, psycho-
logical, and social dimension features [55]. However, there
is no instrument among the multidimensional fatigue
scales that is used globally and that has been translated
into Korean and tested for reliability and validity. In con-
sequence, we did not use a multidimensional instrument.
Although this study did not conclusively demonstrate
the effectiveness of acupuncture for CFS and ICF, the re-
sults could serve as a reference in the treatment of pa-
tients with chronic fatigue of unknown causes.
Conclusions
The results of this study suggest that 4 weeks of body
acupuncture therapy added to usual care can improve
fatigue symptoms of CFS and ICF patients.Additional files
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